Top

Annals of Surgical Oncology

Published in:

01-02-2006

HER-2/neu Expression in Primary Breast Cancer With Sentinel Lymph Node Metastasis

Authors: S. David Nathanson, MD, Robert Slater, MD, Deborah DeBruyn, BS, Alissa Kapke, MS, Michael Linden, MD

Published in: Annals of Surgical Oncology | Issue 2/2006

Abstract

Background

Amplification of the protein product of the HER-2/neu oncogene in primary breast cancer specimens is associated with an adverse prognosis. We hypothesized that overexpression of HER-2/neu would predict metastases to the sentinel lymph nodes (SLNs).

Methods

A retrospective review of a prospective nonrandomized evaluation of 1055 clinically node-negative breast cancer patients undergoing 1063 SLN biopsies was performed. HER-2/neu analysis was performed by immunohistochemistry and, in selected cases, by fluorescence in situ hybridization. Clinical, demographic, surgical, radiological, and pathologic data were analyzed by using generalized estimating equations logistic regression models.

Results

Two hundred thirty-two (23.6%) of 985 operations in which the SLN was found at operation resulted in positive nodes. In a multivariate analysis, size (P < .0001) and HER-2/neu overexpression (P = .026) were independent predictors of SLN metastasis.

Conclusions

Size is a known predictor of SLN metastasis in the modern SLN era, as it was in the pre-SLN eras. HER-2/neu was found to be significantly predictive of SLN metastasis in our study. We anticipate a future when even the relatively minor procedure of SLN biopsy might be avoided with the predictive information gained from studying the pathology and molecular markers of primary breast cancers.

Albertini JJ, Lyman GH, Cantor A, et al. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA 1996;276:1818–1822CrossRefPubMed

Olson JA Jr, Fey J, Winawer J, et al. Sentinel lymphadenectomy accurately predicts nodal status in T2 breast cancer. J Am Coll Surg 2000;191:593–9CrossRefPubMed

Noguchi M. Sentinel lymph node biopsy and breast cancer. Br J Surg 2002;89:21–34PubMed

Edge SB, Niland JC, Bookman MA, et al. Emergence of sentinel node biopsy in breast cancer as standard-of-care in academic comprehensive cancer centers. J Natl Cancer Inst 2003;95:1514–21PubMed

Maggard MA, Lane KE, O’Connell JB, et al. Beyond the clinical trials: how often is sentinel lymph node dissection performed for breast cancer? Ann Surg Oncol 2005;12:41–7CrossRefPubMed

Veronesi U, Paganelli G, Viale G, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 2003;349:546–53CrossRefPubMed

Clark GM. Prognostic and predictive factors. In: Harris JR, Lippman ME, Morrow M, Osborne CK, eds. Diseases of the Breast. 2nd ed. Philadelphia: Lippincott Williams & Wilkins, 2000: 489–514

Schwartz GF, Giuliano AE, Veronesi U. The consensus conference committee: proceedings of the consensus conference of the role of sentinel lymph node biopsy in carcinoma of the breast. April 19–22, 2001, Philadelphia, Pennsylvania. Cancer 2002; 94:2542–51CrossRefPubMed

Grube BJ, Hansen NM, Ye X, Giuliano AE. Tumor characteristics predictive of sentinel node metastases in 105 consecutive patients with invasive lobular carcinoma. Am J Surg 2002;184:372–6CrossRefPubMed

10.

Rivadeneira MD, Rache M, Simmons MD, et al. Predictive factors associated with axillary lymph node metastases in T1a and T1b breast carcinomas: analysis in more than 900 patients. J Am Coll Surg 2000;191:1–6PubMed

11.

Olivotto I, Jackson J, Matas D, et al. Prediction of axillary lymph node involvement of women with invasive breast carcinoma: a multivariate analysis. Cancer 1998;83:948–55CrossRefPubMed

12.

Fein D, Fowble B, Hanlon A, et al. Identification of women with T1-T2 breast cancer at low risk of positive axillary nodes. J Surg Oncol 1997;65:34–9CrossRefPubMed

13.

Chen M, Palleschi S, Khoynezhad A, et al. Role of primary breast cancer characteristics in predicting positive sentinel lymph node biopsy results: a multivariate analysis. Arch Surg 2002;137:606–9PubMed

14.

Cady B. Simplification of breast cancer surgery. Ann Surg Oncol 2005;12:6–8CrossRefPubMed

15.

Mendez JE, Fey JV, Cody H, et al. Can sentinel lymph node biopsy be omitted in patients with favorable breast cancer histology? Ann Surg Oncol 2005;12:24–8CrossRefPubMed

16.

van de Vijver MJ, He YD, van’t Veer IJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999–2009CrossRefPubMed

17.

Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177–80PubMed

18.

Pegram MD, Lipton A, Hayes DF, et al. Phase II study of receptor-enhanced chemosensitivity using a recombinant humanized anti-p185HER-2/neu monoclonal antibody plus cisplatinum in patients with HER-2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998;16:2659–69PubMed

19.

Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells 1998;16:413–28PubMed

20.

Nathanson SD. Insights into the mechanisms of lymph node metastasis. Cancer 2003;98:413–23CrossRefPubMed

21.

Yang W, Klos K, Yang Y, et al. ErbB2 over expression correlates with increased expression of vascular endothelial growth factors A, C, and D in human breast carcinoma. Cancer 2002;94:2855–61PubMed

22.

Nathanson SD, Wachna DL, Gilman D, et al. Pathways of lymphatic drainage from the breast. Ann Surg Oncol 2001;8:837–43PubMed

23.

Liang K-Y, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986;73:13–22.

24.

Zeger SL, Liang K-Y. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986;42:121–30PubMed

25.

Choi SH, Barsky SH, Chang HR. Clinicopathologic analysis of sentinel lymph node mapping in early breast cancer. Breast J 2003;9:153–62CrossRefPubMed

26.

Paik S, Hazan R, Fisher ER, et al. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein over expression in primary breast cancer. J Clin Oncol 1990;8:103–10PubMed

27.

Schechter AL, Hung MC, Vaidyanathan L, et al. The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor. Science 1985;229:976–8PubMed

28.

Reese DM, Slamon DJ. HER-2/neu signal transduction in human breast and ovarian cancer. Stem Cells 1997;15:1–8PubMedCrossRef

29.

Charpin C, Garcia S, Bouvier C, et al. c-erbB-2 oncoprotein detected by automated quantitative immunocytochemistry in breast carcinomas correlates with patients’ overall and disease-free survival. Br J Cancer 1997;75:1667–73PubMed

30.

Lovekin C, Ellis IO, Locker A, et al. C-erb-2 oncoprotein expression in primary and advanced breast cancer. Br J Cancer 1991;63:439–43PubMed

31.

DiGiovanna MP, Stern DF, Edgerton SM, et al. Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients. J Clin Oncol 2005;6:1152–60

32.

Konecny GE, Meng Y, Untch M, et al. Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Cancer Res 2004;10:1706–16PubMed

33.

Linderholm B, Grankvist K, Wilking N, et al. Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment. J Clin Oncol 2000;18:1423–31PubMed

34.

Manders P, Beex LV, Tjan-Heijnen VC, et al. The prognostic value of vascular endothelial growth factor in 574 node-negative breast cancer patients who did not receive adjuvant systemic therapy. Br J Cancer 2002;87:772–8CrossRefPubMed

35.

Zeillinger R, Kury F, Czerwenka K, et al. Her-2 amplification, steroid receptors and epidermal growth factor receptor in primary breast cancer. Oncogene 1989;4:109–14PubMed

Title: HER-2/neu Expression in Primary Breast Cancer With Sentinel Lymph Node Metastasis
Authors: S. David Nathanson, MD
Robert Slater, MD
Deborah DeBruyn, BS
Alissa Kapke, MS
Michael Linden, MD
Publication date: 01-02-2006
Publisher: Springer-Verlag
Published in: Annals of Surgical Oncology / Issue 2/2006
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/ASO.2006.03.032

Keynote webinar | Spotlight on medication adherence

Springer Medicine

HER-2/neu Expression in Primary Breast Cancer With Sentinel Lymph Node Metastasis

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2006

The Role of Genetic Markers— NAP1L1, MAGE-D2, and MTA1—in Defining Small-Intestinal Carcinoid Neoplasia

[11C]Metahydroxyephedrine and [18F]Fluorodeoxyglucose Positron Emission Tomography Improve Clinical Decision Making in Suspected Pheochromocytoma

Minimally Invasive Video-Assisted Thyroidectomy for Follicular Neoplasm: Is There an Advantage Over Conventional Thyroidectomy?

Macrophage Inflammatory Protein-2 Promotes Angiogenesis, Cell Migration, and Tumor Growth in Hepatic Metastasis

Induction Cisplatin and Paclitaxel Followed by Combination Chemoradiotherapy with 5-Fluorouracil, Cisplatin, and Paclitaxel Before Resection in Localized Esophageal Cancer: A Phase II Report

Hepatoma-Derived Growth Factor Is a Novel Prognostic Factor for Hepatocellular Carcinoma